Omeros has submitted Narsoplimab for EMA approval to treat TA-TMA, citing a 3-times survival boost and 61% response rate. The data included over 130 patients from an expanded access program. HC Wainwright reaffirmed a $9 target. However, shareholder concerns grew after key FDA questions were muted during a meeting, fuelling calls for transparency.